

Table S3: Follow-up Time, Number of Events, Incidence Rates, and Hazards Ratios; Incident Patients in Hemodialysis Centers Using Darbepoetin Alfa vs. Epoetin Alfa (Restricted to Patients who were reportedly ESA-naïve)

Outcomes	Sample Size	Follow-up Time (years)	Number of Events	Incidence Rate (per 1000 person-years)	Unadjusted HR (95% CI)	Model 1, HR (95% CI)	Model 2, HR (95% CI)
Mortality	11558	12422.51	3279	263.96	1.12 (1.03, 1.22)	1.03 (0.95, 1.12)	1.01 (0.92, 1.10)
Cardiovascular Mortality	11558	12422.51	1241	99.90	1.13 (0.99, 1.30)	1.04 (0.90, 1.19)	1.01 (0.87, 1.17)
Stroke	5474	5964.48	136	22.80	1.29 (0.83, 1.98)	1.30 (0.84, 2.02)	1.23 (0.79, 1.91)
Myocardial Infarction	5474	5916.88	202	34.14	1.18 (0.84, 1.68)	1.17 (0.82, 1.67)	1.11 (0.77, 1.60)
Composite (Stroke, MI, Cardiovascular Mortality)	5474	5821.34	836	143.61	1.20 (1.01, 1.42)	1.15 (0.96, 1.37)	1.13 (0.95, 1.35)